Holdings
Frazier Life Sciences Management, L.P.
As of Jun 30, 2026, Frazier Life Sciences Management, L.P. reported 36 positions worth US$3.91B. Largest: Mirum Pharmaceuticals, Inc., Erasca, Inc. and Mbx Biosciences, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | 7.68M | US$899M | no change | Jun 30, 2026 |
| Erasca, Inc. | 25M | US$458M | +300K | Jun 30, 2026 |
| Mbx Biosciences, Inc. | 6.65M | US$367M | no change | Jun 30, 2026 |
| Arcutis Biotherapeutics, Inc. | 9.87M | US$259M | no change | Jun 30, 2026 |
| Trevi Therapeutics, Inc. | 9.94M | US$185M | −100 | Jun 30, 2026 |
| Krystal Biotech, Inc. | 481K | US$179M | no change | Jun 30, 2026 |
| Maze Therapeutics, Inc. | 5.03M | US$150M | +466K | Jun 30, 2026 |
| Phathom Pharmaceuticals, Inc. | 12.5M | US$135M | no change | Jun 30, 2026 |
| Palvella Therapeutics, Inc. | 882K | US$135M | no change | Jun 30, 2026 |
| Bridgebio Pharma, Inc. | 1.55M | US$115M | −1.9M | Jun 30, 2026 |